All News
Best of 2023: How Being a Patient Taught Me to Be a Better Doctor
When I was accepted into medical school, my Dad (a trauma surgeon) taught me that as a doctor I should not judge and do my best not to let my personal views interfere with how I manage and interact with my patients.
Read Article
AutoAbs in poly/dermatomyositis - ANA+ 50% to 80%, but not helpful in Dx. Look for MSA Abs - espec antisynthetase ABs (anti-Jo-1), but also newer Abs: MDA-5, TIFF-1 gamma, NXP-2 (to be discussed #RNL24 Dr. Christopher-Stine) https://t.co/ZRlMPE48qX https://t.co/kxD1jw832C https://t.co/afC617tbmq
Dr. John Cush RheumNow ( View Tweet)
GNSC-001 gene therapy w/ a recombinant adeno-assoc. viral vector expressing IL-1Ra, to block IL-1. GNSC-001 now in a phase Ib, 50 pt, 10 center USA trial to assess its efficacy in Knee OA. Given as single injx in the affected joint; results in late 2024 https://t.co/jW9FHlGyC2 https://t.co/Dbv15Flqlv
Links:
Dr. John J Cush RheumNow ( View Tweet)
Global temporal trends in MSK disorders in women of childbearing age increasing in138 countries, 24 decreasing & 42 w. flat trends. In 2019, the prevalence was 354 million w/ India, with China, USA, Indonesia & Brazil highest w/ 51% of global prevalence https://t.co/8nn4lTtNU2 https://t.co/BdkR3aXsZO
Dr. John Cush RheumNow ( View Tweet)
Full Read review of #PMR in Lancet:
- Start @ 12·5–25mg prednisone qd
- Remission in most but, relapses in 40–60%
- Onset sudden; AM stiffness predominates; Shoulders>Pelvic
~50% have distal MSK Sxs
- US: look for B/L sub-acromial/deltoid bursitis https://t.co/NwrbdMMdLU https://t.co/eRls0fLMJs
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA: cutaneous hallmarks of dermatomyositis. Printable Patient education overview. https://t.co/S7MaAz6fX2 https://t.co/5ETcQRz8Fd
Links:
Dr. John Cush RheumNow ( View Tweet)
Plantar Fasciitis study of 180 PF patients shows no clinically meaningful difference between pts treated with patient advice plus heel cup alone (PA) versus PA and lower limb exercise (PAX) versus PAX plus corticosteroid injection (PAXI) https://t.co/X5Q1MlmkzW https://t.co/NtbLQv6b2q
Dr. John Cush RheumNow ( View Tweet)
Best of 2023: PMR: glad or bad tidings?
“Life was turned upside down overnight” – PMR patient.
https://t.co/l7jZei5Kfm https://t.co/Ct3qlHd34P
Dr. John Cush RheumNow ( View Tweet)
Best of 2023: EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome
https://t.co/QQ2IEEMQVy https://t.co/M4NHkasFz6
Dr. John Cush RheumNow ( View Tweet)
Best of 2023: 2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease
The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic CPPD disease is unknown.
https://t.co/gsCtfHzn4Z https://t.co/lIaf36epZY
Dr. John Cush RheumNow ( View Tweet)
Best of 2023: How Being a Patient Taught Me to Be a Better Doctor
Since I can remember, I always wanted to be a doctor. My dad was a trauma surgeon and my mom a nurse.
https://t.co/JE4QoJy4jp https://t.co/jrJoqRD30P
Dr. John Cush RheumNow ( View Tweet)
Best of 2023: LAVLI - A New Autoinflammatory Disorder
NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene.
https://t.co/5nzq6KvOpy https://t.co/Y2MCXkGck2
Dr. John Cush RheumNow ( View Tweet)
Does King Charles have Sausage Digits (dactylitis) or OA? https://t.co/HpOdaXAxff https://t.co/HpOdaXAxff https://t.co/IrjJcxUG9b
Links:
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of Steroids in hosp community-acquired pneumonia (CAP). 18 studies, 4661 pts. Corticosteroids reduced mortality in more severe CAP(RR 0.62; 0.45 to 0.85), but not less severe CAP(RR 1.08). Steroids lower need for mech ventilation, ICU https://t.co/1QbuCZRXze https://t.co/16qiqIatJq
Dr. John Cush RheumNow ( View Tweet)
Denosumab Reduces Type II Diabetes Risk. The British Medical Journal has published a matched cohort analysis demonstrating that adults receiving denosumab had a lower risk of NIDDM compared with those taking oral bisphosphonates for osteoporosis. https://t.co/vZALPMU8lI https://t.co/yGvDLHIp5y
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab in Hidradenitis Supprativa (HS) - results of 2 phase III BE HEARD I & II trials show Week 16 50% HS Responses to be 48% and 52% (vs PBO 29% and 32%). >75% maintained response out to wk 48; at wk 48, a 75% HS response seen in 55%. https://t.co/vAMPWV1gKi
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Great Rheum Meetings
What makes for a great Rheumatology CME meeting?
https://t.co/tdb2crz8XP https://t.co/ZnMIhZpejO
Dr. John Cush RheumNow ( View Tweet)
Best of 2023: 25 Great Women in Rheumatology
https://t.co/9WgGbpILGb https://t.co/YN8QAHtyab
Dr. John Cush RheumNow ( View Tweet)
NEJM - Clinical Images. Sleeve Sign and Inverse Gottron’s Papules in Anti-MDA5 Dermatomyositis. Erythematous plaques/patches on lateral aspects upper arms &; red patches, papules, pustules on ventral palms https://t.co/UHKGePi6TK
Dr. John Cush RheumNow ( View Tweet)
Livedo reticularis is a painless, cyanotic cutaneous mottling in a fishnet pattern, often on extremities > trunk & exaggerated by cold. NOT specific but may be assoc w/ fibromyalgia, Raynauds, atheromatous or autoimmune Dz, hyperviscosity, thrombotic Dz https://t.co/8tGz1hIDiA https://t.co/3mw2RwTEeL
Dr. John Cush RheumNow ( View Tweet)
